Sentman CL - Search Results

1

NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.

Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. Weiss T, et al. Among authors: sentman cl. Cancer Res. 2018 Feb 15;78(4):1031-1043. doi: 10.1158/0008-5472.CAN-17-1788. Epub 2017 Dec 8. Cancer Res. 2018. PMID: 29222400 Free article.

2

Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: sentman cl. Cancer Res. 2006 Jun 1;66(11):5927-33. doi: 10.1158/0008-5472.CAN-06-0130. Cancer Res. 2006. PMID: 16740733

3

NK cell receptors as tools in cancer immunotherapy.

Sentman CL, Barber MA, Barber A, Zhang T. Sentman CL, et al. Adv Cancer Res. 2006;95:249-92. doi: 10.1016/S0065-230X(06)95007-6. Adv Cancer Res. 2006. PMID: 16860660 Review.

4

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.

Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Barber A, et al. Among authors: sentman cl. Cancer Res. 2007 May 15;67(10):5003-8. doi: 10.1158/0008-5472.CAN-06-4047. Cancer Res. 2007. PMID: 17510432

5

Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.

Zhang T, Barber A, Sentman CL. Zhang T, et al. Among authors: sentman cl. Cancer Res. 2007 Nov 15;67(22):11029-36. doi: 10.1158/0008-5472.CAN-07-2251. Cancer Res. 2007. PMID: 18006849

6

Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Barber A, et al. Among authors: sentman cl. Exp Hematol. 2008 Oct;36(10):1318-28. doi: 10.1016/j.exphem.2008.04.010. Epub 2008 Jul 2. Exp Hematol. 2008. PMID: 18599182 Free PMC article.

7

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Huarte E, et al. Among authors: sentman cl. Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3. Cancer Res. 2008. PMID: 18768667 Free PMC article.

8

Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.

Barber A, Rynda A, Sentman CL. Barber A, et al. Among authors: sentman cl. J Immunol. 2009 Dec 1;183(11):6939-47. doi: 10.4049/jimmunol.0902000. Epub 2009 Nov 13. J Immunol. 2009. PMID: 19915047 Free PMC article.

9

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Barber A, Meehan KR, Sentman CL. Barber A, et al. Among authors: sentman cl. Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6. Gene Ther. 2011. PMID: 21209626 Free PMC article.

10

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Zhang T, Sentman CL. Zhang T, et al. Among authors: sentman cl. Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31. Cancer Res. 2011. PMID: 21282338 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters